For a 69-year-old patient with a past medical history of coronary artery disease, peripheral vascular disease, status post four coronary stents and leg stents, and a history of smoking, what is the recommended cholesterol management given LDL 95 mg/dL, total cholesterol 187 mg/dL, triglycerides 111 mg/dL, HDL 75 mg/dL, target LDL <55 mg/dL, inability to afford evolocumab (Repatha), and the patient’s refusal to increase the statin dose due to concern about adverse effects?

Recommended Cholesterol Management

You should aggressively pursue alternative strategies to achieve the LDL <55 mg/dL target, specifically by adding ezetimibe if not already maximized, exploring patient assistance programs for PCSK9 inhibitors, and addressing statin concerns through education about the proven mortality benefit versus theoretical adverse effects in this very high-risk patient. 1

Risk Stratification

This patient meets criteria for very high-risk ASCVD based on:

• Multiple major ASCVD events (4 coronary stents + leg stents = history of multiple revascularizations)
• Symptomatic PAD (leg stents indicate this)
• History of smoking (high-risk condition)
• CAD with multiple interventions

1 defines very high-risk as either multiple major ASCVD events OR one major event plus multiple high-risk conditions—this patient has both.

Current Gap Analysis

• Current LDL: 95 mg/dL
• Target LDL: <55 mg/dL (appropriate for very high-risk)
• Gap: 40 mg/dL reduction needed
• Current regimen: Atorvastatin 40mg + Ezetimibe 10mg

Stepwise Management Algorithm

Step 1: Maximize Current Therapy

Increase atorvastatin to 80mg daily (high-intensity statin). The 2018 ACC/AHA guidelines explicitly recommend high-intensity statin therapy for very high-risk ASCVD patients 1. The patient's concern about adverse effects must be addressed directly:

• Absolute benefit in this patient: PAD patients in the FOURIER trial had 3.5% absolute risk reduction in major cardiovascular events with intensive LDL lowering 2
• Statin adverse effects are largely reversible and the mortality benefit far outweighs theoretical risks in this very high-risk population
• Consider a trial period with close monitoring (2-4 weeks) to assess tolerability before abandoning the approach

Step 2: Verify Ezetimibe Optimization

Confirm the patient is actually taking ezetimibe 10mg daily (adherence check). If not already on it, this is mandatory. The 2018 ACC/AHA guidelines state it is reasonable to add ezetimibe when LDL remains ≥70 mg/dL on maximally tolerated statin 1.

Step 3: Address PCSK9 Inhibitor Access

This patient has a Class IIa indication for PCSK9 inhibitor (reasonable to add) since:

• Very high-risk ASCVD
• LDL ≥70 mg/dL on statin + ezetimibe
• Would meet criteria even at current therapy level 1

Specific actions for cost barrier:

1. Manufacturer patient assistance program: Amgen (Repatha manufacturer) offers copay cards and patient assistance for those who qualify financially 3
2. Alternative PCSK9 inhibitor: Try alirocumab (Praluent) as insurance formularies may differ
3. Prior authorization: Document very high-risk status, multiple ASCVD events, and on-target medical therapy—this strengthens approval likelihood
4. Appeal process: If denied, formal appeal citing guideline recommendations and very high-risk status

The 2022 BMJ guideline supports PCSK9 inhibitors when LDL remains ≥100 mg/dL on maximal statin + ezetimibe, though this patient is close at 95 mg/dL 4.

Step 4: PAD-Specific Considerations

PAD patients derive particularly large absolute benefit from intensive LDL lowering. The FOURIER trial demonstrated:

• Evolocumab reduced major adverse limb events by 42% (HR 0.58) 2
• Absolute risk reduction was twice as large in PAD patients (3.5%) versus non-PAD patients (1.6%) for cardiovascular events 2
• Benefit extended to preventing acute limb ischemia, major amputation, and urgent revascularization 2

This makes the case for PCSK9 inhibitor access even stronger—the patient faces not just cardiovascular death/MI/stroke risk, but also limb loss risk.

Common Pitfalls to Avoid

1. Accepting suboptimal LDL control: With LDL 95 mg/dL and target <55 mg/dL, this represents a 73% higher LDL than goal—unacceptable in very high-risk disease
2. Deferring to patient statin concerns without education: The mortality benefit is proven and substantial; adverse effects are typically mild and reversible
3. Not pursuing PCSK9 inhibitor access aggressively: Multiple pathways exist beyond list price (assistance programs, appeals, alternative agents)
4. Forgetting the limb-specific benefit: PAD patients benefit from LDL lowering for both cardiovascular AND limb outcomes 2

Practical Next Steps

1. Immediate: Schedule dedicated visit to discuss statin dose increase with specific data on PAD outcomes and reversibility of side effects
2. Within 1 week: Initiate manufacturer assistance program application for Repatha or alternative PCSK9 inhibitor
3. Within 2 weeks: If statin increase accepted, recheck lipids at 6-8 weeks
4. Ongoing: Document all attempts to optimize therapy for insurance appeals and continuity of care

The European guidelines recommend LDL <55 mg/dL for very high-risk patients with combination therapy as needed 4, and this patient clearly qualifies. The current plan of continuing atorvastatin 40mg is inadequate and leaves the patient at substantially elevated risk for both cardiovascular events and limb loss.